tbuckley/cabot-search huggingface dataset:
THU0252 Decreased Expression of Immunoregulatory Protein Programmed Death Ligand-1 (PD-L1) in Systemic Lupus Erythematosus (SLE) Placenta: Table 1.
Authors: A.M. Stevens, M. Yuasa, G. Deutsch
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The increased rates of preeclampsia, pre-term birth, and intra-uterine growth restriction in SLE pregnancy are only partially explained by the vascular effects of anti-phospholipid antibodies. SLE patients themselves are on average born preterm, suggesting a heritable defect in maternal-fetal tolerance. PD-L1 is one candidate gene, in that it has been implicated in the both autoimmunity and maternal-fetal tolerance: PD-L1 is expressed on healthy antigen presenting cells to downregulate inflammatory responses, and also on placental trophoblasts at the maternal-fetal interface, where it inhibits alloreactive T cells. Peripheral blood antigen presenting cells from SLE patients are deficient in PD-L1 expression compared to remission or healthy controls. Little is known about placental costimulatory molecules in women with autoimmune diseases. <h3>Objectives</h3> This study tested the hypothesis that placental PD-L1 expression is abnormally regulated in SLE pregnancy. <h3>Methods</h3> Expression of PD-L1 was quantified by immunohistochemistry in placentas from 6 SLE patients, 7 rheumatoid arthritis patients (RA) and 9 healthy control women obtained from the Global Alliance for the Prevention of Prematurity and Stillbirth Repository. PD-L1 mRNA expression was assayed by RT-PCR and normalized to GAPDH expression. PD-L1 on peripheral CD14+/CD11c+ monocytes was assayed by flow cytometry. Significant differences between groups were tested by T-test. <h3>Results</h3> By immunostaining, PD-L1 expression in SLE placentas was low compared to control groups. PD-L1 mRNA expression correlated with protein expression, although the differences were not significant. A limited analysis of CD45 and CD43 co-expression suggested that a subset of maternal T lymphocytes expressed PDL-1 but that fetal cells did not. The mean gestational age was lower in SLE (27 weeks, range 18–39) compared to RA (38, range 29–40) and controls (34, range 19–40), but there was not a strong correlation between gestational age and PD-L1 expression (R<sup>2</sup> 0.18). Three SLE patients exhibited placental insufficiency, with relatively low PD-L1 expression (18 compared to 24 in healthy SLE). On peripheral blood monocytes, PD-L1 expression was low in juvenile SLE patients compared to healthy controls (55% of SLE monocytes v. 93% of healthy monocytes, p=0.001). Although in the normal range, mothers of SLE patients also had relatively low PD-L1 expression compared to control mothers (87% v. 94%, p=0.04). <h3>Conclusions</h3> Placental PD-L1 expression is dysregulated in women with SLE. Inadequate expression of PDL-1 in the placentas of patients with SLE could result in loss of maternal-fetal tolerance, <i>contributing to the high rate of pregnancy complications in SLE.</i> <h3>Disclosure of Interest</h3> None declared
Two ATM variants, IVS10-6T>G and 1420L>F, and breast cancer risk
Authors: Georgia Chenevix-Trench, Anna Marsh, Amanda Spurdle, Deborah Thompson, Antonis Antoniou, Doug Easton, Mark Jenkins, John Hopper, Kumkum Khanna, Nic Waddell, Melissa Southey, Andrea Tesoriero, Yvonne Thorstenson, Peter Oefner, David Goldgar
Journal: Cancer Research (2005)

Proc Amer Assoc Cancer Res, Volume 46, 2005

1883 

The ATM gene is mutated in ataxia-telangiectasia (A-T). Female A-T heterozygotes have a 2-7 fold increased risk of breast cancer. We previously reported high risk associations between certain ATM variants and breast cancer. In order to estimate the risks of breast cancer associated with ATM variants more precisely, we have examined two ATM variants, IVS10-6T>G and 1420L>F, in additional cases and controls from the same Australian cohorts previously used to estimate the risk of breast cancer associated with IVS10-6T>G. A total of 775 and 84 population-based controls were genotyped for the IVS10-6T>G and 1420L>F ATM variants respectively, as were index cases from 378 and 373 non-BRCA1 /2 breast cancer families. Penetrance was estimated by Bayes factor analysis. The allele frequencies of ATM IVS10-6T>G and 1420L>F estimated from controls were 0.005 (95% CI = 0.002 to 0.009) and 0.012 (95% CI = 0.001 to 0.042) respectively. We identified three new multiple-case breast cancer families with ATM IVS10-6T>G, and seven families with 1420L>F. Combining with the two IVS10-6T>G families previously reported, the estimated penetrance to age 70 of IVS10-6T>G was 17.2% (95% CI = 4.7% to 37.5%). For 1420L>F, the estimated average penetrance was 4.8% (95% CI 1.7% to 10.1%). In conclusion, we found no evidence that the ATM 1420L>F variant increases breast cancer risk, and little evidence that IVS10-6T>G confers an elevated risk. Analysis of additional families will be necessary to define more precisely the risk, if any, associated with IVS10-6T>G. .
A Phase II Trial of Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) in Previously Treated Patients with AL Amyloidosis.
Authors: Giovanni Palladini, Paola Russo, Letizia Zenone Bragotti, Andrea Foli, Francesco Musca, Francesca Lavatelli, Vittorio Perfetti, Laura Obici, Stefano Perlini, Giampaolo Merlini
Journal: Blood (2009)
Epoetin Beta (Neorecormon®) Treatment for Anemia of Patients with Non-Myeloid Hematological Malignancy under Chemotherapy: Results of a Large Prospective Cohort Study.
Authors: Corinne Haïoun, Norbert Ifrah, Philippe Casassus, Bruno Audhuy, Malek Aoudjhane, Jamile Frayfer, Stephanie Rouanet, Pascal Bleuzen, Arash Jenabian, Thierry Facon
Journal: Blood (2007)
Incidence, Clinical Characteristics and Survival of Malignant Lymphomas in the Province of Modena (Italy); a Population-Based Study.
Authors: Stefano Luminari, Marina Cesaretti, Ivan Rashid, Elsa Pennese, Caterina Mammi, Antonella Montanini, Elisa Barbolini, Monica Bellei, Luigi Marcheselli, Giovanni Partesotti, Alessia Bari, Antonio Maiorana, Tullio Artusi, Massimo Federico
Journal: Blood (2006)
Invasive Fungal Infections (IFI) In Lymphoproliferative Disorders: Epidemiology, Outcome and Prognostic Factors
Authors: Maria Luisa Pioltelli, Annamaria Nosari, Marta Riva, Laura Marbello, Laura Paris, Alessandra Tedeschi, Francesca Ricci, Eleonora Vismara, Speziale Valentina, Chiara Rusconi, Vittorio Ruggero Zilioli, Cristina Gabutti, Alfredo Molteni, Rosa Greco, Antonino Greco, Emanuele Ravano, Enrica Morra
Journal: Blood (2011)
Non-Hodgkin’s Lymphoma Refractory to First Line Therapy: Incidence, Associated Clinical and Histological Factors, and Outcome among 503 Newly Diagnosed Patients.
Authors: Angela Gueli, Daniele Caracciolo, Manuela Zanni, Luciana Bergui, Paolo Gavarotti, Marco Ladetto, Andrea Filippi, Roberto Passera, Mario Boccadoro, Corrado Tarella
Journal: Blood (2007)
Imaging of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-HBED-CC-PSMA PET/CT
Authors: Susanne Lütje, Benedikt Gomez, Joseph Cohnen, Lale Umutlu, Martin Gotthardt, Thorsten D. Poeppel, Andreas Bockisch, Sandra Rosenbaum-Krumme
Journal: Clinical Nuclear Medicine (2016)

Purpose The prostate-specific membrane antigen (PSMA) was shown to be overexpressed on the neovasculature of several malignancies. Here, the role of 68Ga-HBED-CC-PSMA PET/CT for the detection of PSMA expression in patients with metastasized differentiated thyroid cancer (DTC) was evaluated. Methods Six patients with iodine-negative and 18F-FDG–positive metastasized DTC (mean TG, 1616 ng/mL) received 71–93 MBq of the 68Ga-labeled PSMA ligand and underwent PET/CT at 62 ± 7 minutes p.i.. Tumor accumulation capacity of the tracer and the detection rate of local recurrences and metastases were compared with 18F-FDG. Tracer uptake was quantified in terms of the SUVmax. Results In 5 of 6 patients, sites of putative metastatic disease could be identified using 68Ga-HBED-CC-PSMA PET/CT. All lesions detected with 68Ga-HBED-CC-PSMA PET/CT (n = 42) were confirmed by 18F-FDG PET/CT or conventional CT imaging. Using 68Ga-HBED-CC-PSMA PET/CT, all tumor lesions identified with 18F-FDG PET/CT imaging could be visualized in 3 of 5 patients. In 2 patients, only the most prominent lesions detected with 18F-FDG PET/CT imaging were visualized by 68Ga-HBED-CC-PSMA PET/CT. 68Ga-HBED-CC-PSMA uptake ranged from low in 1 patient (mean SUVmax 3.3) to intermediate (1 patient; mean SUVmax, 6.1) to intense (3 patients; mean SUVmax, 12.8, 16.2, and 18.3). The highest SUVmax values were observed for a bone lesion, reaching 39.7. Conclusions These preliminary results indicate that 68Ga-HBED-CC-PSMA PET/CT might be suitable for staging of patients with metastasized DTC. 68Ga-HBED-CC-PSMA PET/CT could be useful for the identification of patients who might qualify for PSMA-targeted radionuclide therapy because of high PSMA uptake.
The Novel Proteasome Inhibitor Carfilzomib Interacts Synergistically with HDAC Inhibitors in ABC- and GC-DLBCL Cells Both in Vitro and In Vivo through Mechanisms Involving JNK Activation, NF-κB Inactivation, and DNA Damage..
Authors: Girija Dasmahapatra, Dmitry Lembersky, Lora Kramer, Jonathan W. Friedberg, Richard I Fisher, Paul Dent, Steven Grant
Journal: Blood (2009)
Monitoring of Wilms’ Tumor 1 Expression As Minimal Residual Disease in Patients with Acute Myeloid Leukemia to Predict Relapse before and after Allogeneic Stem Cell Transplantation
Authors: Remy Dulery, Olivier Nibourel, Vincent Elsermans, David Beauvais, Arthur Simonnet, Jordan Gauthier, Valérie Coiteux, Leonardo Magro, Bruno Quesnel, Claude Preudhomme, Ibrahim Yakoub-Agha
Journal: Blood (2014)
Safety, Tolerability and Activity of Ofatumumab, Bendamustine and Dexamethasone Combination As First-Line Treatment of Mantle-Cell Lymphoma in the Elderly: A Multicenter Study
Authors: Michele Magni, Massimo Di Nicola, Carmelo Carlo-Stella, Liliana Devizzi, Anna Guidetti, Paola Matteucci, Simonetta Viviani, Stefania Zambelli, Andrés JM Ferreri, Alessandro Rambaldi, Francesco Di Raimondo, Corrado Tarella, Andrea Gallamini, Francesco Nobile, Daniele Vallisa, Angelo Michele Carella, Caterina Patti, Giovanni Quarta, Vittorio Rizzoli, Fabio Benedetti, Paolo Corradini, Alessandro M. Gianni
Journal: Blood (2011)
SP0173 Polymyalgia Rheumatica: Improving Outcomes for Patients in Primary Care
Authors: T. Helliwell
Journal: Annals of the Rheumatic Diseases (2016)

Polymyalgia rheumatic (PMR) is the most common inflammatory arthritis managed in primary care settings. The majority of clinical care is typically provided by General Practitioners (GPs) with evidence suggesting that current management is suboptimal. This talk will highlight some of the key challenges faced by GPs highlighting areas where the diagnosis, monitoring and long term care can be improved. <h3>Disclosure of Interest</h3> None declared
Activation of K-Ras in Arf-Null Mice Is Not Sufficient for Malignant Transformation of Post-Germinal Center B-Cells
Authors: Chelsea D. Mullins, Mack Y. Su, Vishwanathan Hucthagowder, Liang Chu, Lan Lu, Shashikant Kulkarni, Ravi Vij, Michael H. Tomasson
Journal: Blood (2012)
Elevated BAFF Is Correlated with Inflammatory Processes in Chronic Graft Versus Host Disease and Supports Increases in Transitional B Cells
Authors: Frances T. Hakim, Najibah Rehman, John Dickinson, Sivasubramanian Baskar, Christoph M. Rader, Edward W. Cowen, Steven Z. Pavletic, Ronald E. Gress
Journal: Blood (2008)
AB1057 risk factors associated with different lumbopelvic patterns of movement
Authors: M. Sarti, D. Ybáñez-García, M.Ά. Fuster-Ortí, L.J. Villaplana-Sarti, R. Expositor-Rodríguez, C. Barrios
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rapid flexion movement increases the loading on the spine and it increases the risk of injuries<sup>1</sup>. In asymptomatic subjects lumbar-dominant and pelvis-dominant patterns of movement during trunk flexion have been observed<sup>2,3</sup>. However, little information about lumbar spine kinematics has been provided. <h3>Objectives</h3> To find out whether exhibiting different lumbopelvic patterns of movement during trunk flexion affects the kinematics of the lumbar spine in terms of velocity of motion. <h3>Methods</h3> Differential lumbar spine and pelvis angular displacement during the time course of a standardised sagittal trunk flexion from an upright position was recorded with an electromagnetic tracking device in 32 asymptomatic females (22.65±3.5 years). Range of motion (ROM) (degrees) for the lumbar spine, pelvis and average angular velocity (degrees/sec) for the entire movement were calculated. Subjects were divided into groups according to moving more in the lumbar spine than in pelvis, group1 (n=17) and vice-versa moving more in the pelvis (at the hip joint) than in lumbar spine, group2 (n=15). The one-way MANOVA followed by F test showed significant differences in lumbar spine velocity between groups. <h3>Results</h3> The lumbopelvic pattern of movement is shown for both groups in the figure. Average angular velocity (degrees/sec) for the spine was significantly (p&lt;0.01) greater in group 1 (18.7±3.8) than in 2 (13.1±2.4). <h3>Conclusions</h3> Changes in the lumbopelvic pattern of movement bring about differences in lumbar spine velocity of motion. Consequently, the risk of injury for the spine may be different for both groups and clinical implications may be different as well. <h3>References</h3> Davis KG, Marras WS. The effects of motion on trunk biomechanics. Clin Biomech. 2000;15:703–17. Nakayama T, Yamamoto I, Fujiwara T, Yamada T. Sagittal Kinematics and Muscular Activities of Torso and Hip During Trunk Flexion and extension. J.Phys.Ther.Sci.2006;18:165–173. Pal P, Milosavljevic S, Sole G, Johnson G. Hip and lumbar continuous motion characteristics during flexion and return in young healthy males. Eur Spine J. 2007;16:741–747. <h3>Acknowledgement</h3> This study has been supported by the following grants:Ref. FIS2001–0070–01, Ref. TIC2001–2786-C02–02, Ref. AP2001–376 <h3>Disclosure of Interest</h3> None declared
Impact of Severe Pain on Outcomes in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Authors: Jong Wook Lee, Jun Ho Jang, Jin Seok Kim, Sung-Soo Yoon, Je-Hwan Lee, Yeo-Kyeoung Kim, Deog-Yeon Jo, Jooseop Chung, Sang Kyun Sohn
Journal: Blood (2011)
Vinorelbine-Cyclophosphamide Compared to Cyclophosphamide in Peripheral Blood Stem Cell Mobilization for Multiple Myeloma
Authors: Sanjay De Mel, Yunxin Chen, Adeline Lin, Eng Soo Yap, Teck Guan Soh, Joanna Mah, Melissa G. Ooi, Sathish Kumar Gopalakrishnan, Lara Kristina Sioco Donato, Nurul Aidah Abdul Halim, Wee-Joo Chng, lip Kun Tan
Journal: Blood (2015)
Solved paradoxes and old hats? The research needed on differentiated selves
Authors: Ilan Dar-Nimrod, Karen Gonsalkorale
Journal: Behavioral and Brain Sciences (2016)

Abstract The idea that differentiated selves almost always improve group outcomes is overly simplistic. We argue that it is essential to distinguish between two distinct elements of differentiated selves – identifiability and specialization – and to identify conditions under which they influence group outcomes. Adopting a group-by-situation perspective, in which group and situation variables are considered jointly, is recommended to generate novel hypotheses.
Single Nucleotide Polymorphisms of the NOD2/CARD15 Gene Are Associated with Significant Increases in Disease Relapse and Mortality in Recipients of an Unrelated Donor Haematopoietic Stem Cell Transplant for Acute Leukaemia.
Authors: Neema P. Mayor, Bronwen E. Shaw, Derralynn A. Hughes, Hazael Maldonado-Torres, J. Alejandro Madrigal, Satish Keshav, Steven G.E. Marsh
Journal: Blood (2006)
Nov/CCN3 Enhances Long-Term Repopulating Activity of Mouse Hematopoietic Stem Cells Via Intergin β3 Signaling Collaborating with Thrombopoietin
Authors: Jun Ishihara, Terumasa Umemoto, Masayuki Yamato, Yoshiko Shiratsuchi, Brian G. Petrich, Hiromitsu Nakauchi, Koji Eto, Toshio Kitamura, Teruo Okano
Journal: Blood (2011)
Intralobular septal thickening on chest CT in a patient with pulmonary amyloidosis: a rare case study
Authors: Yasuhito Suzuki, Junpei Saito, Ryuichi Togawa, Hiroyuki Minemura, Mitsuru Munakata
Journal: Thorax (2016)

A 54-year-old female presented with chronic dry cough and dyspnoea over 3 months and was referred to our outpatient clinic. She had no history of smoking, allergy or respiratory disorders. Chest X-ray demonstrated bilateral upper lung predominant consolidation (figure 1A). Chest CT revealed extensive upper lobe predominant subpleural consolidation with air bronchograms as well as extensive ground glass opacities (GGOs) with intralobular septal thickening (figure 1B–D). Mediastinal lymphadenopathy in stations 4R and 10R with no calcification was observed. There were no crackles on auscultation with oxygen saturation of 95% on room air despite a wide range of abnormal shadows on chest X-ray and CT. Based on the available clinical and radiographic findings, the differential diagnosis encompassed pulmonary sarcoidosis, malignant lymphoma, bronchoalveolar carcinoma, lymphangitis carcinomatosa and amyloidosis.



Figure 1 
Chest X-rays and CT scans. Chest …
When Does High Risk for Stroke Become Low Risk After Atrial Fibrillation Ablation?
Authors: Francis E. Marchlinski, Pasquale Santangeli
Journal: JAMA Cardiology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Abstract #801: EGF-induced MMP-9 expression is mediated by the JAK3/ERK pathway, but not by the JAK3/STAT-3 pathway in a SKBR3 breast cancer cell line
Authors: Sangmin Kim, Wonshik Han, Jae Hyuck Choi, Hye In Lim, Se-Kyung Lee, Wan Wook Kim, Jee Soo Kim, Jung-Han Kim, Jun-Ho Choe, Seok Jin Nam, Jeong Eon Lee, Jung-Hyun Yang
Journal: Cancer Research (2009)

AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

The number of epidermal growth factor receptors (EGFRs) and their ligands are highly expressed in malignant tumor cells. The EGF signaling pathway is also activated in up to one-third of patients with breast cancer. In this study, we investigated the novel function of the JAK3 inhibitor, WHI-P131, on EGF-induced MMP-9 expression and the regulatory mechanism of EGF-induced MMP-9 expression in SKBR3 cells. We observed that EGF increased MMP-9 mRNA and protein expression in a dose-dependent manner. EGF also induced the phosphorylation of EGFR, ERK, and STAT-3, and these effects were inhibited by the EGFR inhibitor, AG1478. To investigate the involvement of the STAT-3 pathway on EGF-induced MMP-9 expression, we pretreated SKBR3 cells with JAK1, JAK2, and JAK3 inhibitors prior to EGF treatment. The results showed that the JAK3 inhibitor, WHI-P131, but not the JAK1 and JAK2 inhibitors, significantly decreased EGF-induced MMP-9 expression. In addition, EGF-induced STAT-3 phosphorylation was only inhibited by WHI-P131. We then transfected cells with adenoviral STAT-3 (Ad-STAT-3), followed by treatment with EGF. Interestingly, EGF-induced MMP-9 expression was decreased by Ad-STAT-3 overexpression in a dose-dependent manner, while basal levels of MMP-9 expression were significantly increased by constitutive active-MEK (CA-MEK) overexpression. EGF-induced ERK phosphorylation was prevented by WHI-P131, but not by JAK1 and JAK2 inhibitors. On the other hand, EGF-induced MMP-9 expression was decreased by the MEK1/2 inhibitor, UO126. Therefore, we suggest, for the first time, that the JAK3 inhibitor, WHI-P131, inhibits EGF-induced STAT-3 phosphorylation as well as ERK phosphorylation. The JAK3/ERK pathway may play an important role in EGF-induced MMP-9 expression in SKBR3 cells.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 801.
A Wharton's Jelly Mesenchymal Stromal Cell Derived 3D Osteogenic Niche Allows for Cord Blood Stem Cell Expansion Using Cytokine-Free Culture Media
Authors: Omar S. Aljitawi, Peggy Keefe, Christianna Henderson, Salem Akel, Sunil Abhyankar, Joseph McGuirk, Michael Detamore, Rama Garimella
Journal: Blood (2011)
Array CGH Analysis for PTCL-U Revealed a Distinct Subgroup with Pathological and Clinical Relevance.
Authors: Masao Nakagawa, Aya Nakagawa-Oshiro, Sivasundaram Karnan, Hiroyuki Tagawa, Shigeo Nakamura, Ichiro Takeuchi, Koichi Ohshima, Masao Seto
Journal: Blood (2007)
Analysis of Stereotyped IGHV Distribution In a Series of 1133 Chronic Lymphocytic Leukemia Patients: The Experience of a Multicenter Italian Study Group
Authors: Francesco Maura, Giovanna Cutrona, Massimo Gentile, Serena Matis, Monica Colombo, Luca Agnelli, Giacomo Tuana, Rosanna Massara, Fabrizio Loiacono, Simona Pedemonte, Daniele Reverberi, Emanuela Anna Pesce, Marta Lionetti, Sonia Fabris, Anna Grazia Recchia, Francesco Di Raimondo, Caterina Musolino, Marco Gobbi, Nicola Di Renzo, Francesca Romana Mauro, Renato Cantaffa, Maura Brugiatelli, Francesco Merli, Simonetta Zupo, Caterina Mammi, Luca Baldini, Francesco Angrilli, Gianni Quintana, Ugo Consoli, Giovanni Bertoldero, Emilio Iannitto, Paolo Di Tonno, Antonio Fragasso, Stefano Molica, Pellegrino Musto, Maria Cristina Cox, Gianluca Festini, Vincenzo Callea, Stefano Sacchi, Giorgio Lambertenghi Deliliers, Robin Foà, Massimo Federico, Agostino Cortelezzi, Fortunato Morabito, Manlio Ferrarini, Antonino Neri
Journal: Blood (2010)
Post-Transfusion Viability of 7-Day Stored Platelet (Plt) Concentrates Prepared after An Overnight Hold of Whole Blood (WB) at 22°C
Authors: Sherrill J. Slichter, Jill Corson, Mary Kay Jones, Esther Pellham, Todd Christoffel, Shawn Bailey, Doug Bolgiano
Journal: Blood (2008)
Long-Term Reconstitution of Transduced Rhesus CD34+ Cells Mobilized by G-CSF and Plerixafor.
Authors: Naoya Uchida, Aylin Bonifacino, Allen E Krouse, Sandra D Price, Ross M Fasano, Gyorgy Csako, Susan F Leitman, Mark E Metzger, Matthew M Hsieh, Joseph J Mattapallil, John F Tisdale, Robert E Donahue
Journal: Blood (2010)
Immunocompromised Status of Patients with Hematologic and Solid Tumor Malignancies: Construction of a Practical Algorithm.
Authors: Trung N Tran, G. Thomas Ray, Patricia Saddier, Michael Trigg, Neil Hayes, Yan Li, David A. Rizzieri, Anthony Stein, David Weber, Jonathan Serody, Ralph Raasch, Laurel Habel
Journal: Blood (2009)
Improved Methodology for Detection of Mutations in the BCR-ABL Fusion Gene That Cause Resistance to the Tyrosine Kinase Inhibitor Imatinib.
Authors: Paul G. Rothberg, Roberto L. Vargas, Jane L. Liesveld, Jainulabdeen J. Ifthikharuddin, Sharon D. Frazier, Susan L. Polochock
Journal: Blood (2006)